Related Experiment Video
Updated: Jul 19, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Published on: January 7, 2018
Drug-induced hypoglycaemia--new insight into an old problem
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|October 10, 2006
Summary
Unintentional use of oral hypoglycaemic agents causes drug-induced hypoglycaemia, especially in the elderly. Inadvertent medication errors in care homes and shared household medications are common culprits.
Area of Science:
- Clinical Toxicology
- Endocrinology
- Geriatric Medicine
Background:
- Drug-induced hypoglycaemia is a significant clinical concern, particularly in patients not prescribed hypoglycaemic medications.
- Identifying the sources of inadvertent exposure is crucial for patient safety and preventing recurrence.
Purpose of the Study:
- To investigate the causes of drug-induced hypoglycaemia in patients without a history of taking hypoglycaemic medications.
- To identify common sources and risk factors associated with inadvertent oral hypoglycaemic agent exposure.
Main Methods:
- Retrospective study analyzing patient data referred to a toxicology laboratory.
- Included patients with suspected drug-induced hypoglycaemia and no known exposure to hypoglycaemic agents.
- Laboratory analysis, including target analysis, was used to detect oral hypoglycaemic agents.
Main Results:
- Oral hypoglycaemic agents were detected in 45% of referred patients.
- Common sources included medication errors in elderly care homes and accidental ingestion of family members' medications.
- Gliclazide and glibenclamide were the most frequently detected agents; most patients recovered fully.
Conclusions:
- Inadvertent use of oral hypoglycaemic agents is a recognized issue, particularly in elderly patients and those with shared medications in households.
- Drug administration errors in residential care facilities require investigation and procedural improvements.
- Healthcare providers must maintain vigilance for potential medication errors in unexplained hypoglycaemia cases.
More Related Videos
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
07:30Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Related Concept Videos
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...